文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

循环肿瘤DNA:泌尿肿瘤学从局限性疾病到转移性疾病的新研究前沿

Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease.
PubMed 文献 · Eur Urol Oncol · 2024-12-02

本综述经PubMed和MEDLINE非系统性检索,纳入关于循环肿瘤DNA(ctDNA)用于泌尿系肿瘤的前瞻性与回顾性同行评议研究、综述及研究摘要。研究发现,在前列腺癌和尿路上皮癌中,ctDNA分数从局限性疾病到转移性疾病成比例增加,提示更高的肿瘤负荷和更具侵袭性的行为;ctDNA似乎有助于改善预后风险分层和治疗选择。肾细胞癌的液体活检数据仍有限,评估预后和预测生物标志物是关键的未满足需求。将ctDNA检测整合到常规临床实践需要患者、临床医生和分子生物学家参与的多学科方法。

要点

  • 在前列腺癌和尿路上皮癌中,ctDNA分数从局限性疾病到转移性疾病成比例增加,提示更高的肿瘤负荷和更具侵袭性的行为。
  • ctDNA似乎是改善预后风险分层和治疗选择的有用工具。
  • 肾细胞癌的液体活检数据仍有限,评估预后和预测生物标志物是关键的未满足需求。

核心结论

  • ctDNA分析有望在不同疾病背景下彻底改变泌尿系肿瘤的管理。
  • 将ctDNA检测整合到常规临床实践需要患者、临床医生和分子生物学家参与的多学科方法。
  • 在ctDNA检测成为常规患者护理的一部分之前,需要多学科方法的进一步研究。

研究设计与样本

  • 非系统性文献综述,检索PubMed和MEDLINE数据库。
  • 纳入关于ctDNA用于泌尿系肿瘤的前瞻性和回顾性同行评议研究、综述文章和研究摘要。

主要发现

  • 若干研究表明,ctDNA分析是一种有前景的工具,可帮助临床医生诊断和管理泌尿系肿瘤。
  • 在前列腺癌和尿路上皮癌中,ctDNA分数从局限性疾病到转移性疾病成比例增加,提示更高的肿瘤负荷和更具侵袭性的行为。
  • ctDNA似乎是改善预后风险分层和治疗选择的有用工具。
  • 肾细胞癌的液体活检数据仍有限,评估预后和预测生物标志物是关键的未满足需求。

临床怎么用

  • ctDNA分析有望在不同疾病背景下彻底改变泌尿系肿瘤的管理。
  • 将ctDNA检测整合到常规临床实践需要患者、临床医生和分子生物学家参与的多学科方法。

局限性

  • 肾细胞癌的液体活检数据仍有限,评估预后和预测生物标志物是关键的未满足需求。
  • 在ctDNA检测成为常规患者护理的一部分之前,需要多学科方法的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Circulating tumor DNA (ctDNA) testing provides valuable prognostic and predictive information for guiding therapeutic choices and monitoring disease progression and drug resistance for urological tumors. Our review focuses on emerging opportunities for ctDNA analysis in urological tumors and the development of potential circulating biomarkers within a multidisciplinary framework to improve personalized treatment. METHODS: A nonsystematic literature review was conducted in the PubMed and MEDLINE databases. Prospective and retrospective peer-reviewed studies, review articles, and research abstracts on the use of ctDNA for urological tumors were included. KEY FINDINGS AND LIMITATIONS: Several studies have demonstrated that ctDNA analysis is a promising tool that can help clinicians in the diagnosis and clinical management of urological tumors. In prostate and urothelial cancers, the ctDNA fraction increases proportionally from localized to metastatic disease, indicating a higher tumor burden and more aggressive behavior. Thus, ctDNA seems to be a useful tool for improving prognostic risk stratification and treatment selection. Data on the use of liquid biopsy in renal cell carcinoma are still limited, and assessment of prognostic and predictive biomarkers is a critical unmet need. CONCLUSIONS AND CLINICAL IMPLICATIONS: ctDNA analysis promises to revolutionize the management of urological tumors in different disease settings. Integration of ctDNA testing in routine clinical practice will require a multidisciplinary approach that involve patients, clinicians, and molecular biologists. PATIENT SUMMARY: We reviewed how testing for tumor DNA in blood (circulating tumor DNA, ctDNA) is used in urological cancers. A great deal of evidence supports the usefulness of this noninvasive test. However, further research via a multidisciplinary approach is needed before ctDNA testing becomes part of routine patient care.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Garofoli M, Maiorano BA, Bruno G, et al. Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease. Eur Urol Oncol. 2024. PMID: 39627072. doi:10.1016/j.euo.2024.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。